Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States

Andrew N. Freedman; Carrie N. Klabunde; Kristine Wiant; Lindsey Enewold; Stacy W. Gray; Kelly K. Filipski; Nancy L. Keating; Debra G.B. Leonard; Tracy Lively; Timothy S. McNeel; Lori Minasian; Arnold L. Potosky; Donna R. Rivera; Richard L. Schilsky; Deborah Schrag; Naoko I. Simonds; Helmneh M. Sineshaw; Jeffery P. Struewing; Gordon Willis; Janet S. de Moor

Journal ArticleOPEN ACCESS

Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States

Freedman A
Klabunde C
Wiant K
et al.

JCO Precision Oncology (2018) (2) 1-13

DOI: 10.1200/po.18.00169

130Citations

116Readers

Abstract

PurposeThere are no nationally representative data on oncologists’ use of next-generation sequencing (NGS) testing in practice. The purpose of this study was to investigate how oncologists in the U...

Cite

CITATION STYLE

APA

Freedman, A. N., Klabunde, C. N., Wiant, K., Enewold, L., Gray, S. W., Filipski, K. K., … de Moor, J. S. (2018). Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCO Precision Oncology, (2), 1–13. https://doi.org/10.1200/po.18.00169

Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States

Abstract

Cite

Register to see more suggestions